Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $96.43 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Lockheed Martin wins $8.4B missile contract modification
• Enanta Pharma loses appeal in Pfizer Paxlovid patent case